

IMMUNOBIOLOGICS

IMMUNOBIOLOGIC	PRIMARY IMMUNIZATION SCHEDULE	BOOSTER SCHEDULE	COMMENTS AND CONTRAINDICATIONS
<p>Pneumococcal Vaccine (Polyvalent, inactivated) (PPSV)</p> <p>PNEUMOVAX® 23 Merck</p>	<p>Selected children 2 years of age and older and high-risk adults (see comments)</p> <p>First: 0.5 mL IM or SC as a single dose</p>	<p>Revaccination not routinely recommended.</p> <p>See comments for list of persons for whom a second dose of PPSV is recommended and for the timing of that dose.</p> <p>Dose: 0.5 mL IM or SC</p>	<p>Children 24-59 months of age who have already received one or more doses of PCV7 and who are at high risk of invasive pneumococcal disease (see below) should be given PPSV (no sooner than 2 months after the last dose of PCV7).</p> <p>PPSV is recommended for the following groups:</p> <p>Immunocompetent persons:</p> <ul style="list-style-type: none"> • Persons aged 65 years and older; • Persons 2-64 years with chronic cardiovascular disease, chronic pulmonary disease, or diabetes mellitus; • Persons 2-64 years with alcoholism, chronic liver disease, or cerebrospinal fluid leaks; • Person 2-64 with a cochlear implant • Persons 19-64 years who have asthma; • Persons 19-64 years who smoke cigarettes (smokers should also receive smoking cessation counseling). • Persons 2-64 years living in special environments or social settings with an identified increased risk of pneumococcal disease or its complications, including residents of nursing homes and other long-term-care facilities <p>Routine use of PPSV is not recommended for Alaska Native or American Indian persons 2-64 years unless they have underlying medical conditions that are PPSV indications. However, in special situations, public health authorities may recommend PPSV for Alaska Natives and American Indians aged 24-59 months or 50 - 64 years who are living in areas in which the risk of invasive pneumococcal disease is increased.</p> <p>Immunocompromised persons:</p> <ul style="list-style-type: none"> • Persons 2 years and over, including those with HIV infection, leukemia, lymphoma, Hodgkin's disease, multiple myeloma, generalized malignancy, chronic renal failure, or nephritic syndrome, • Persons 2 years and over receiving immunosuppressive chemotherapy (including corticosteroids); and those who have received an organ or bone marrow transplant. • Persons 2 years and over with sickle cell disease or functional of an anatomic asplenia <p>Revaccination: A second dose of PPSV is recommended 5 years after the first dose of PPSV for persons ≥2 years who are immunocompromised, have sickle cell disease, or functional or anatomic asplenia..</p> <p>Persons aged 65 years and older should be administered a second dose of pneumococcal vaccine if they received the vaccine more than 5 years previously, and were younger than 65 years of age at the time of the first dose.</p> <p>Adverse Reactions: Pain, swelling or erythema at the injection site; moderate systemic reactions (such as fever and myalgia) are not common (<1%), and more severe systemic adverse reactions are rare.</p> <p>Contraindications & Precautions: Pregnancy, unless high-risk. History of severe hypersensitivity to a prior dose or to thimerosal. Moderate or severe illness until condition improved.</p>